Donna Huang

[Green Room Comms. @GR_Comms]

Tips for Communicating with the C-suite: speak their language, don’t use #PR jargon, present with one slide, keep it simple, and benchmark against competition, but make it specific. #ExLPRSummit

[Donna Huang @donnabu32]

So nice to meet you today! Enjoyed our conversations! @AmysAmerica

[Amy Atwood @AmysAmerica]

How to have a successful conversation with the C-Suite? Use their language, stick to one slide and benchmark - @donnabu32 @ExLPharmaPR #ExLPRSummit

[AstraZenecaUS @AstraZenecaUS]

We fight for hearts and so much more. Our employees started #AmericanHeartMonth off right by sharing everything they fight for.

[AstraZenecaUS @AstraZenecaUS]

Today, we are proud to announce full results from our DECLARE trial: https://t.co/tPPK8xTUY2 #AHA18

[AstraZenecaUS @AstraZenecaUS]

Today we visited #CapitolHill for a #hearthealth workout with @mytrainerbob and connected with members of Congress about the needs of #heartattacksurvivors

[Donna Huang @donnabu32]

@SouthwestAir this was reported immediately and Not even an update? I recommend you... Now not sure. #yousayyoulovecustomers #wherethelove https://t.co/bdU66mDTK9

[Mariam Santee @MariamKoohdary]

Son left headphones on Flt 1630 on Saturday to Aruba. He put in a claim and we have not heard one word. Help a kid! @Southwest Airlines

[AstraZenecaUS @AstraZenecaUS]

AZ seeks to further reduce cardiovascular morbidity and mortality, & organ damage by addressing multiple #CVD risk factors. #ACC17

[AstraZenecaUS @AstraZenecaUS]

CVD-REAL study fast facts. More details here: https://t.co/PTWTN9OSlv #ACC17

[AstraZenecaUS @AstraZenecaUS]

Now available: new data in #diabetes from the CVD-REAL Study at #ACC17. https://t.co/mQmHb0Epl9

[AstraZeneca @AstraZeneca]

With the projected increase in diabetes cases, we’re taking a holistic approach to CVMD to improve patient outcomes. #ACC17

[AstraZenecaUS @AstraZenecaUS]

How can real-world data better inform the care of CVMD patients? #ACC17

[AstraZenecaUS @AstraZenecaUS]

Before you depart #ACC17, be sure to stop by the AZ booth to learn about the latest developments in treating patients w/ #ACS

[AstraZenecaUS @AstraZenecaUS]

Tomorrow at #ACC17 we will present new data from CVD-REAL, the first large real-world evidence study of its kind.

[AstraZenecaUS @AstraZenecaUS]

We’ve been following the science in CVMD for 100+ years and will continue to focus on improving patient outcomes. #ACC17

[AstraZenecaUS @AstraZenecaUS]

Day 2 of #ACC17, here we go!

[AstraZenecaUS @AstraZenecaUS]

Real-world data complements insights gathered from clinical trials #ACC17

[AstraZeneca @AstraZeneca]

Referred to as the silent killer due to its lack of overt symptoms, cardiovascular disease causes 30% of all deaths globally. #ACC17 #CVD

[AstraZenecaUS @AstraZenecaUS]

Our CV outcomes trials will contribute clinical knowledge to help individualize treatment approaches among diverse patient groups. #ACC17

[AstraZenecaUS @AstraZenecaUS]

Science & regulatory developments in treatment for patients w/ #ACS continue to evolve across #CVMD. Visit our #ACC17 booth to learn more.

[AstraZenecaUS @AstraZenecaUS]

AZ supports some of the largest & most representative CV outcomes trials in the fastest-growing classes of #diabetes meds. #ACC17 #CVD #T2D